Esther Rajavelu Sells 20,689 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu sold 20,689 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $16,137.42. Following the completion of the transaction, the chief financial officer now owns 724,720 shares in the company, valued at $565,281.60. This trade represents a 2.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Spero Therapeutics Stock Down 1.6 %

Shares of SPRO opened at $0.86 on Friday. Spero Therapeutics, Inc. has a 52-week low of $0.74 and a 52-week high of $1.89. The company has a 50-day simple moving average of $0.99 and a 200-day simple moving average of $1.19. The company has a market capitalization of $47.07 million, a PE ratio of 12.33 and a beta of 0.61.

Analysts Set New Price Targets

Several research analysts have weighed in on SPRO shares. Evercore ISI downgraded Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research note on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a report on Thursday, January 30th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.